Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/580821
Full metadata record
DC FieldValueLanguage
dc.coverage.spatial
dc.date.accessioned2024-08-06T06:02:06Z-
dc.date.available2024-08-06T06:02:06Z-
dc.identifier.urihttp://hdl.handle.net/10603/580821-
dc.description.abstractColorectal cancer (CRC), often known as colon cancer, typically originates as newlinea benign polyp in the colon or rectum and spreads slowly over 10 20 years. About newline9.4% of cancer-related deaths in 2020 were caused by CRC. Survival rates from CRC newlineare significantly affected by both recurrence and metastasis. In systemic therapy, the newlineproblem of non-targeted drug dispersion is of paramount importance. The main newlineworries and key grounds for chemotherapy failure are side effects and resistance to newlinemedicines, both of which are caused by this lack of specificity. To tackle these newlinechallenges, polymeric nanoparticles (PNP) were developed as transporter devices for newlineCRC therapy, with the ability to encapsulate diverse medications, shield therapeutic newlinemolecules, and give numerous advantages above their counterparts in bulk. To the newlineextent of our information this is the first work to demonstrate that functionalized newlinePolymeric nanoparticle loaded CAP and TQ can effectively be used as a synergistic newlinecombination to induce apoptosis, which could be used to kill off cancer cells. newlineAim newlineThis research aims to formulate a Nano-based drug delivery system targeting newlinecolorectal cancer. The objectives of the study are: newline1. To formulate, optimize, and evaluate pluronic polymer functionalized newlinenanocarrier system loaded Capecitabine and Thymoquinone. newline2. To assess the anticancer activity of optimized formulation by conducting in newlinevitro and in vivo studies. newline
dc.format.extent
dc.languageEnglish
dc.relation
dc.rightsuniversity
dc.titlePluronic polymer functionalized polymeric nanoparticles loaded capecitabine and thymoquinone for targeting colorectal cancer an experimental study
dc.title.alternative
dc.creator.researcherPrasiddhi R.Raikar
dc.subject.keywordCapecitabine; Thymoquinone; Colorectal cancer; PLGA; Polymeric nanoparticles; Galactosylation; Eudragit; Targeted Nanoformulation
dc.subject.keywordClinical Pre Clinical and Health
dc.subject.keywordPharmacology and Toxicology
dc.description.note
dc.contributor.guidePanchaxari M. Dandagi
dc.publisher.placeBelgaum
dc.publisher.universityKLE University
dc.publisher.institutionFaculty of Pharmacy
dc.date.registered
dc.date.completed2024
dc.date.awarded2024
dc.format.dimensions
dc.format.accompanyingmaterialNone
dc.source.universityUniversity
dc.type.degreePh.D.
Appears in Departments:Faculty of Pharmacy

Files in This Item:
File Description SizeFormat 
80_recommendation.pdfAttached File646.41 kBAdobe PDFView/Open
ms. prasiddhi r.raikar_.pdf14.36 MBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: